This inventor holds 3 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Merck Sharp & Dohme LLC. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Kaila A Margrey: Innovator in Pharmaceutical Research
Introduction
Kaila A Margrey is a prominent inventor based in Cambridge, MA (US). She has made significant contributions to the field of pharmaceutical research, particularly in the development of innovative treatments for diseases associated with LRRK2 kinase.
Latest Patents
Kaila holds a patent for "N-linked isoquinoline amides as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof." This invention focuses on certain 2-aminoquinazoline derivatives that act as potent inhibitors of LRRK2 kinase. These compounds may be beneficial in treating or preventing diseases such as Parkinson's Disease, among others. The patent also encompasses pharmaceutical compositions that include these compounds and their applications in medical treatments.
Career Highlights
Kaila is currently associated with Merck Sharp & Dohme LLC, where she continues to advance her research in the pharmaceutical sector. Her work is pivotal in the ongoing quest for effective therapies for neurodegenerative diseases.
Collaborations
Kaila collaborates with esteemed colleagues, including Peter H Fuller and Anmol Gulati, to further enhance the impact of her research and innovations.
Conclusion
Kaila A Margrey's contributions to pharmaceutical research exemplify her dedication to improving healthcare through innovative solutions. Her work on LRRK2 inhibitors is a testament to her commitment to addressing critical health challenges.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile